Docetaxel (Taxotere ) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

• Published in: British journal of cancer 1994-08, Vol.70 (2), p.380-383
• Main Authors: Sulkes, A, Smyth, J, Sessa, C, Dirix, L Y, Vermorken, J B, Kaye, S, Wanders, J, Franklin, H, LeBail, N, Verweij, J
• Format: Article
• Language: English
• Subjects: Adult; Aged; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Docetaxel; Female; Humans; Male; Middle Aged; Paclitaxel - adverse effects; Paclitaxel - analogs & derivatives; Paclitaxel - therapeutic use; Stomach Neoplasms - drug therapy; Taxoids
• ISSN: 0007-0920; 1532-1827
• DOI: 10.1038/bjc.1994.310

Thirty-seven eligible patients, median age 59 years (range 37-72) and median performance status 1 (0-2), with advanced, untreated, measurable gastric carcinoma were given docetaxel, 100 mg m-2 i.v. over 60 min without premedication, once every 3 weeks. Metastatic sites included the liver in 12 patients and retroperitoneal lymph nodes in 16. Eight of the 33 evaluable patients (24%) achieved a partial remission for a median of 7.5 months (3-11+). An additional 11 patients had stabilisation of disease. The patients received a median of four cycles of docetaxel (range 1-8) for a total of 156 courses. Dose reduction was necessary in 30 cycles; 14 cycles were delayed a mean of 3 days. Haematological toxicity consisted mainly of non-cumulative neutropenia, with a median nadir count of 0.35 x 10(9) l-1 (0.04-1.64) and eight episodes (5%) of leucopenic fever; non-haematological toxicities included alopecia, mild nausea and vomiting and allergic manifestations such as skin rash and pruritus. There were no drug-related deaths. Our data indicate that docetaxel is an active agent in advanced gastric cancer; further clinical investigations seem warranted.